PRLD – prelude therapeutics incorporated (US:NASDAQ)
Stock Stats
News
Prelude Therapeutics Announces Pricing of $90.0 Million Underwritten Offering
Prelude Therapeutics Presents Preclinical Data from Development Candidate, PRT13722, a First-in-Class, Orally Bioavailable, Potent and Highly Selective KAT6A Degrader at American Association for Cancer Research (AACR) Annual Meeting 2026 [Yahoo! Finance]
Prelude Therapeutics Presents Preclinical Data from Development Candidate, PRT13722, a First-in-Class, Orally Bioavailable, Potent and Highly Selective KAT6A Degrader at American Association for Cancer Research (AACR) Annual Meeting 2026
Prelude Therapeutics Announces the Appointment of Charles Morris, M.D. as Chief Medical Officer
Prelude Therapeutics Announces Acceptance of Preclinical Abstract for PRT13722, a First-in-Class Oral KAT6A Selective Degrader at the 2026 AACR Annual Meeting [Yahoo! Finance]
Form SCHEDULE 13D/A Prelude Therapeutics Filed by: BAKER BROS. ADVISORS LP
Form 4 Prelude Therapeutics For: Apr 21 Filed by: 667, L.P.
Form 424B5 Prelude Therapeutics
Form 8-K Prelude Therapeutics For: Apr 20
Form 8-K Prelude Therapeutics For: Apr 20
Top News Gainers
Top News Decliners
Live Event: How Top Hedge Funds Use News To Make Money From The Stock Market & How Ordinary People Are Copying Their Strategies
If you could use the news to make money from the stock market, would you? Join us on our live online event where you’ll discover this simple scientific method that has allowed ordinary people get a huge return from the stock market without excessive risk.